EMA to review MDCO's oritavancin

The Medicines Co. (NASDAQ:MDCO) said EMA accepted for review an MAA for IV oritavancin to treat complicated skin and skin tissue infections (cSSTI) caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The product is under review in the U.S. to treat acute bacterial skin and skin structure infections (ABSSSI), with an Aug. 6 PDUFA date. The Medicines Co. gained the semi-synthetic lipoglycopeptide antibiotic through its 2009 acquisition of Targanta Therapeutics Corp. ...